Open Access

Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series

  • Authors:
    • Francesco Schettini
    • Irene De Santo
    • Carmen G. Rea
    • Martina Viggiani
    • Giuseppe Buono
    • Carmine De Angelis
    • Cinzia Cardalesi
    • Rossella Lauria
    • Mario Giuliano
    • Valeria Forestieri
    • Guglielmo Thomas
    • Pierfrancesco Maione
    • Gennaro Limite
    • Antonello Accurso
    • Luca Malorni
    • Sabino De Placido
    • Grazia Arpino
  • View Affiliations

  • Published online on: March 11, 2020     https://doi.org/10.3892/mco.2020.2016
  • Pages: 456-460
  • Copyright: © Schettini et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Palbociclib is a potent cyclin‑dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first‑ and second‑line treatment in hormone receptor (HR)+, human epidermal growth factor receptor (HER)2‑ metastatic breast cancer. There is evidence that palbociclib may reverse endocrine therapy resistance and that it may also be added to ongoing endocrine therapy beyond progression to obtain clinical benefit. The aim of the present study was to explore this possibility in 5 patients who received palbociclib + fulvestrant following disease progression while under treatment with fulvestrant alone. The median progression‑free survival was not reached during a median follow‑up of 25 months, and the most frequent best response was stable disease. Three patients remained under treatment on the last re‑evaluation. All patients had highly endocrine‑sensitive disease and had previously received fulvestrant for ≥12 months. The hypothesis that a selected subpopulation of patients with HR+/HER2‑ metastatic breast cancer may benefit from the addition of palbociclib to ongoing endocrine therapy beyond disease progression merits further investigation.
View References

Related Articles

Journal Cover

May 2020
Volume 12 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Schettini, F., De Santo, I., Rea, C.G., Viggiani, M., Buono, G., De Angelis, C. ... Arpino, G. (2020). Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series. Molecular and Clinical Oncology, 12, 456-460. https://doi.org/10.3892/mco.2020.2016
MLA
Schettini, F., De Santo, I., Rea, C. G., Viggiani, M., Buono, G., De Angelis, C., Cardalesi, C., Lauria, R., Giuliano, M., Forestieri, V., Thomas, G., Maione, P., Limite, G., Accurso, A., Malorni, L., De Placido, S., Arpino, G."Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series". Molecular and Clinical Oncology 12.5 (2020): 456-460.
Chicago
Schettini, F., De Santo, I., Rea, C. G., Viggiani, M., Buono, G., De Angelis, C., Cardalesi, C., Lauria, R., Giuliano, M., Forestieri, V., Thomas, G., Maione, P., Limite, G., Accurso, A., Malorni, L., De Placido, S., Arpino, G."Palbociclib added to ongoing endocrine therapy for hormone receptor‑positive HER2‑negative metastatic breast cancer: A case report series". Molecular and Clinical Oncology 12, no. 5 (2020): 456-460. https://doi.org/10.3892/mco.2020.2016